What is the recommended management approach for rosacea, including skincare, topical and systemic treatments, and indications for laser therapy?

Rosacea Management

For rosacea management, initiate treatment based on the predominant clinical feature using a phenotype-directed approach: topical ivermectin 1% or azelaic acid 15% for papules/pustules, topical brimonidine 0.33% or oxymetazoline 1% for persistent erythema, and vascular lasers for telangiectasia, with combination therapy required for moderate-to-severe presentations. 1, 2

Treatment Framework by Phenotype

The ROSCO 2019 consensus panel established that optimal therapy must be tailored to the specific signs and symptoms present, rather than following a rigid algorithm 1, 2. Treatment selection depends on which clinical features are most prominent and troublesome to the patient.

For Inflammatory Papules and Pustules

First-line topical agents:

• Ivermectin 1% cream once daily demonstrates superior efficacy compared to metronidazole 0.75%, with 83% reduction in lesion counts versus 73.7%, and longer time to relapse (115 days vs 85 days) 2
• Azelaic acid 15% gel or foam shows high-certainty evidence for efficacy, with 51% of patients achieving clear/almost clear status at 12 weeks 2, 3
• Encapsulated benzoyl peroxide 5% (E-BPO) is the newest FDA-approved option (2022), demonstrating rapid onset by week 2 with 44-50% achieving 2-grade IGA improvement and sustained efficacy up to 52 weeks 2
• Minocycline foam 1.5% (FDA-approved 2020) provides 64% lesion reduction with low irritation rates (1.5%) 2
• Metronidazole 0.75-1% remains effective with 65% lesion reduction, though less potent than newer agents 2

Systemic therapy:

• Doxycycline 40 mg modified-release (anti-inflammatory dose) is the preferred oral agent, showing 45.7% IGA success rate and noninferior efficacy to doxycycline 100 mg with better tolerability 2, 3
• Reserve for moderate-to-severe disease or when topical therapy alone is insufficient
• Oral isotretinoin has moderate-to-high certainty evidence for refractory papulopustular disease 3

For Persistent Erythema

Topical vasoconstrictors provide symptom control but do not treat underlying inflammation:

• Brimonidine gel 0.33% once daily has high-certainty evidence, reducing erythema within 30 minutes with sustained effect up to 12 hours 3, 2
• Oxymetazoline HCl cream 1% once daily shows moderate-certainty evidence with similar efficacy profile 3
• These agents address vascular dysregulation but require continuous use; discontinuation leads to return of erythema 2

For Telangiectasia

Vascular-targeted procedures are the definitive treatment:

• Pulsed-dye laser (PDL) and intense pulsed light (IPL) have low-to-moderate certainty evidence for reducing telangiectasia and erythema 1, 3
• Topical agents do not effectively treat fixed vascular changes 2

For Phymatous Changes

• Surgical or laser therapy is indicated for clinically noninflamed ("fibrotic" or "burnt-out") phyma 1
• For clinically inflamed ("active") phyma, treat the inflammatory component first with systemic therapy before considering procedural intervention

For Ocular Rosacea

• Lid hygiene is first-line for mild symptoms
• Artificial tears for mild burning/stinging
• Oral omega-3 fatty acids have moderate-certainty evidence for efficacy 3
• Cyclosporine ophthalmic emulsion shows low-certainty evidence 3
• Refer to ophthalmology for moderate-to-severe disease with blepharitis, blurred vision, foreign body sensation, photophobia, or interpalpebral hyperemia that doesn't respond to basic measures 1, 4

Combination Therapy Approach

Moderate and severe presentations require combination treatment 1. The panel unanimously agreed (17/17) that multiple features can be treated simultaneously:

• Combine topical anti-inflammatory agent (ivermectin, azelaic acid, or E-BPO) with oral doxycycline 40 mg for moderate-to-severe papulopustular disease
• Add topical vasoconstrictor (brimonidine or oxymetazoline) when persistent erythema coexists with inflammatory lesions
• Consider laser/IPL therapy for telangiectasia alongside medical management 5, 6

If first-line treatment fails, either switch to an alternative first-line option or add an additional first-line agent 1.

Essential Skincare Foundation

All patients require:

• Sun protection SPF 30+ daily
• Gentle cleansers (avoid harsh scrubs or astringents)
• Moisturizers to maintain skin barrier
• Trigger avoidance (identify and avoid individual triggers like alcohol, spicy foods, temperature extremes, stress) 2, 1, 5

Maintenance Therapy

Use minimum treatment necessary to maintain control 1. The approach depends on treatment modality:

• Topical metronidazole, ivermectin, or azelaic acid are appropriate for long-term maintenance 5
• Continue treatments for sufficient duration before switching (specific to each agent)
• Up to two-thirds of patients relapse when therapy is discontinued 2
• E-BPO 5% demonstrates sustained efficacy for 52 weeks without tachyphylaxis 2

Critical Pitfalls to Avoid

Treatment adherence is poor: Up to 89% of patients experiencing treatment-related adverse effects discontinue therapy within one month 2. Select agents with better tolerability profiles (E-BPO 5%, ivermectin, minocycline foam) to improve adherence.

Skin irritation expectations: Some agents cause early irritation—counsel patients that this may occur but often improves with continued use 2. The microencapsulation technology in E-BPO 5% specifically addresses this concern.

Inadequate treatment duration: Most studies show improvement by 3-4 weeks, but many agents demonstrate continued benefit beyond 12 weeks without plateau 2. Don't prematurely discontinue effective therapy.

Missing ocular involvement: Children with ocular rosacea often present with corneal involvement and may have subtle facial signs 4. Screen for ocular symptoms including burning, foreign body sensation, and photophobia.

Underdiagnosis in darker skin: Rosacea is difficult to diagnose in patients with darker skin tones due to difficulty visualizing erythema and telangiectasia 4. Look for other features like papules, pustules, and patient-reported flushing.

Treatment Selection Algorithm

1. Identify predominant feature(s): papules/pustules, erythema, telangiectasia, phyma, or ocular involvement
2. Assess severity: mild (single feature, limited extent) vs moderate-to-severe (multiple features, extensive involvement)
3. For mild disease: Start with single topical agent targeting predominant feature
4. For moderate-to-severe disease: Initiate combination therapy (topical + systemic for papulopustular; topical anti-inflammatory + vasoconstrictor for mixed presentation)
5. Add procedural therapy for telangiectasia or phymatous changes as needed
6. Transition to maintenance once control achieved, using minimum effective therapy
7. Monitor for relapse and reinitiate treatment promptly if features recur

The evidence strongly supports ivermectin 1% and azelaic acid 15% as the most effective topical anti-inflammatory agents based on head-to-head comparisons 2, while E-BPO 5% offers the newest option with excellent tolerability and rapid onset 2.